Pan-immune-inflammation value: a new predictor of cardiac scar in hospitalized myocarditis patients.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-08-01 Epub Date: 2025-07-30 DOI:10.1080/17520363.2025.2540771

Semih Kalkan, Serçin Özkök, İhsan Demirtaş, Ömer Fakih Türkmen, Ali Fuat Tekin, Mustafa Ozan Gürsoy, Ahmet Karaduman, Volkan Gürler

{"title":"Pan-immune-inflammation value: a new predictor of cardiac scar in hospitalized myocarditis patients.","authors":"Semih Kalkan, Serçin Özkök, İhsan Demirtaş, Ömer Fakih Türkmen, Ali Fuat Tekin, Mustafa Ozan Gürsoy, Ahmet Karaduman, Volkan Gürler","doi":"10.1080/17520363.2025.2540771","DOIUrl":null,"url":null,"abstract":"Background: Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging indicates myocardial scarring and has prognostic value in myocarditis. The Pan-Immune-Inflammation Value (PIV) is a novel biomarker reflecting systemic inflammation; however, its association with LGE in myocarditis remains uninvestigated. This study aims to evaluate whether PIV levels can predict the presence of LGE in patients with myocarditis.Aims: We retrospectively analyzed 141 patients with myocarditis between 2021 and 2024. PIV, troponin levels, and other inflammatory markers were analyzed for their association with LGE.Results: LGE was observed in 68.8% of the patients, with a higher proportion of males in the LGE+ group. The LGE+ group showed significantly elevated levels of PIV (1.661.2 ± 22.269) and troponin (786.2 ± 10.711 ng/L) compared to the LGE- group. Multivariate regression analysis confirmed PIV (OR: 1.002, p = 0.005) and troponin (OR: 1.003, p = 0.001) as predictors of LGE. ROC analysis identified a PIV threshold of >1153.2, achieving 95% specificity with a positive predictive value of 92.9% for LGE presence.Conclusions: Our findings indicate that elevated PIV levels are significant predictors of LGE, suggesting that PIV may serve as a valuable tool in assessing risk and guiding follow-up strategies for patients with myocarditis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"647-656"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344797/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2540771","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging indicates myocardial scarring and has prognostic value in myocarditis. The Pan-Immune-Inflammation Value (PIV) is a novel biomarker reflecting systemic inflammation; however, its association with LGE in myocarditis remains uninvestigated. This study aims to evaluate whether PIV levels can predict the presence of LGE in patients with myocarditis.

Aims: We retrospectively analyzed 141 patients with myocarditis between 2021 and 2024. PIV, troponin levels, and other inflammatory markers were analyzed for their association with LGE.

Results: LGE was observed in 68.8% of the patients, with a higher proportion of males in the LGE+ group. The LGE+ group showed significantly elevated levels of PIV (1.661.2 ± 22.269) and troponin (786.2 ± 10.711 ng/L) compared to the LGE- group. Multivariate regression analysis confirmed PIV (OR: 1.002, p = 0.005) and troponin (OR: 1.003, p = 0.001) as predictors of LGE. ROC analysis identified a PIV threshold of >1153.2, achieving 95% specificity with a positive predictive value of 92.9% for LGE presence.

Conclusions: Our findings indicate that elevated PIV levels are significant predictors of LGE, suggesting that PIV may serve as a valuable tool in assessing risk and guiding follow-up strategies for patients with myocarditis.

查看原文本刊更多论文

泛免疫炎症值：心肌炎住院患者心脏瘢痕的新预测指标

背景：心脏磁共振成像晚期钆增强（LGE）提示心肌瘢痕形成，对心肌炎有预后价值。泛免疫炎症值（Pan-Immune-Inflammation Value， PIV）是一种反映全身性炎症的新型生物标志物；然而，其与LGE在心肌炎中的关系仍未被研究。本研究旨在评估PIV水平是否可以预测心肌炎患者LGE的存在。目的：我们回顾性分析了2021年至2024年间141例心肌炎患者。分析PIV、肌钙蛋白水平和其他炎症标志物与LGE的关系。结果：68.8%的患者出现LGE， LGE+组男性比例较高。与LGE-组相比，LGE+组PIV（1.661.2±22.269）和肌钙蛋白（786.2±10.711）水平显著升高。多因素回归分析证实PIV （OR: 1.002, p = 0.005）和肌钙蛋白（OR: 1.003, p = 0.001）是LGE的预测因子。ROC分析确定PIV阈值为>1153.2，特异性为95%，LGE存在的阳性预测值为92.9%。结论：我们的研究结果表明，PIV水平升高是LGE的重要预测因素，这表明PIV可能是评估心肌炎患者风险和指导随访策略的有价值的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.